| KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ, Jana KUBÁTOVÁ, Eva HLAVÁČKOVÁ, Kateřina ČERNÁ PILÁTOVÁ, Pavel MAZANEK, Klára VEJMĚLKOVÁ, Vítězslav DUŠEK, Pavel TINKA, Martin BALÁŽ, Tomáš MERTA, Zuzana KUTTNEROVÁ, Terézia TUREKOVÁ, Zdeněk PAVELKA, Petra POKORNÁ, Hana PÁLOVÁ, Marie MLNAŘÍKOVÁ, Marta JEŽOVÁ, Renata KELLNEROVÁ, Sarka KOZAKOVA, Ondřej SLABÝ, Dalibor VALÍK a Jaroslav ŠTĚRBA. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients. International journal of cancer. HOBOKEN: WILEY, 2024, 12 s. ISSN 0020-7136. Dostupné z: https://dx.doi.org/10.1002/ijc.35062. |
Další formáty:
BibTeX
LaTeX
RIS
@article{2418115,
author = {Kýr, Michal and Múdry, Peter and Polášková, Kristýna and Zdražilová Dubská, Lenka and Demlová, Regina and Kubátová, Jana and Hlaváčková, Eva and Černá Pilátová, Kateřina and Mazanek, Pavel and Vejmělková, Klára and Dušek, Vítězslav and Tinka, Pavel and Baláž, Martin and Merta, Tomáš and Kuttnerová, Zuzana and Tureková, Terézia and Pavelka, Zdeněk and Pokorná, Petra and Pálová, Hana and Mlnaříková, Marie and Ježová, Marta and Kellnerová, Renata and Kozakova, Sarka and Slabý, Ondřej and Valík, Dalibor and Štěrba, Jaroslav},
article_location = {HOBOKEN},
doi = {http://dx.doi.org/10.1002/ijc.35062},
keywords = {cancer vaccine; immunotherapy; metronomic chemotherapy; N-of-1; rare cancer},
language = {eng},
issn = {0020-7136},
journal = {International journal of cancer},
title = {Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients},
url = {https://onlinelibrary.wiley.com/doi/10.1002/ijc.35062},
year = {2024}
}
TY - JOUR
ID - 2418115
AU - Kýr, Michal - Múdry, Peter - Polášková, Kristýna - Zdražilová Dubská, Lenka - Demlová, Regina - Kubátová, Jana - Hlaváčková, Eva - Černá Pilátová, Kateřina - Mazanek, Pavel - Vejmělková, Klára - Dušek, Vítězslav - Tinka, Pavel - Baláž, Martin - Merta, Tomáš - Kuttnerová, Zuzana - Tureková, Terézia - Pavelka, Zdeněk - Pokorná, Petra - Pálová, Hana - Mlnaříková, Marie - Ježová, Marta - Kellnerová, Renata - Kozakova, Sarka - Slabý, Ondřej - Valík, Dalibor - Štěrba, Jaroslav
PY - 2024
TI - Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
JF - International journal of cancer
PB - WILEY
SN - 00207136
KW - cancer vaccine
KW - immunotherapy
KW - metronomic chemotherapy
KW - N-of-1
KW - rare cancer
UR - https://onlinelibrary.wiley.com/doi/10.1002/ijc.35062
N2 - A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.
ER -
KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ, Jana KUBÁTOVÁ, Eva HLAVÁČKOVÁ, Kateřina ČERNÁ PILÁTOVÁ, Pavel MAZANEK, Klára VEJMĚLKOVÁ, Vítězslav DUŠEK, Pavel TINKA, Martin BALÁŽ, Tomáš MERTA, Zuzana KUTTNEROVÁ, Terézia TUREKOVÁ, Zdeněk PAVELKA, Petra POKORNÁ, Hana PÁLOVÁ, Marie MLNAŘÍKOVÁ, Marta JEŽOVÁ, Renata KELLNEROVÁ, Sarka KOZAKOVA, Ondřej SLABÝ, Dalibor VALÍK a Jaroslav ŠTĚRBA. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients. \textit{International journal of cancer}. HOBOKEN: WILEY, 2024, 12 s. ISSN~0020-7136. Dostupné z: https://dx.doi.org/10.1002/ijc.35062.
|
